Loading…
← CockpitCompetitor Analysis › 2186.HK Luye Pharma Group Ltd.Open in the cockpit ↗

Luye Pharma Group Ltd.2186.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major
Momentum weak 30
Mkt cap
$736M
US dollars, full cap
Free float
53%
of shares outstanding
$/day
$4.67M
20-day average traded
Fwd P/E
7.1×
forward earnings
ROIC−WACC
-2.0 pp
WACC 6.8%
Hurdle
-14 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · HKDHK$1.54
1D+0.3%
1W-8.6%
1M-8.6%
3M-22.6%
6M-32.5%
YTD-43.8%
1Y-50.3%
ATR %3.7%
52w lowhigh52.6% off high

What Luye Pharma does

Employees: 5,221

Luye Pharma at a glance

Size Luye Pharma (2186.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $736M, the 657th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$1.54 on 18 Nov 2026.

Performance Over six months the shares fell 32.5%, against -7.3% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 3rd lowest of 20 in its peer set.

Growth Revenue grew 2.8% over the last twelve months (peer median +3.5%); the operating margin is 18.5% (peer median 8.8%).

Valuation It trades at 7.1× forward earnings against a peer median of 16.1× (cheapest of 6).

Price implies For today's price to make sense, revenue must grow about -12% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -14 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.0 points below its cost of capital (6.8% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 932186.HK 68
Six months, rebased to 100: Luye Pharma against the median of its 20 peers (local-currency closes).

Luye Pharma financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$6.85BHK$6.84BHK$6.57BHK$6.79BHK$6.96B
Revenue growth—+4%-3%-2%—
Gross profitHK$4.36BHK$4.51BHK$4.38BHK$4.64BHK$4.81B
EBITDAHK$2.23BHK$2.27BHK$2.11BHK$1.79BHK$1.82B
Net incomeHK$780MHK$671MHK$512MHK$589MHK$703M
Free cash flowHK$1.17BHK$1.59B-HK$493MHK$1.04BHK$1.72B
Capital expenditureHK$749MHK$1.09BHK$1.85BHK$1.29BHK$1.35B
Total debtn/aHK$10.5BHK$11.0BHK$9.27BHK$10.2B

Quarterly statements and history in the cockpit →

Luye Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-25%0%+25%+50%300705688566600530688799SGMT2171002907603998057045343001LXRX002390NVCTBLISSGVS2186.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Luye Pharma is the large dot.

Fundamentals: revenue growth against valuation

-5%0%+5%+10%+15%20×40×30070568856668879960399845342186.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Luye Pharma is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%3007056885666005306004790029076039980024243001002390600829BLISSGVS2186.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Luye Pharma is the large dot.

Luye Pharma competitors and peer comparison

How Luye Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Luye Pharma against its 20 peers (data as of 18 Nov 2026)
Measure2186.HKPeer medianRank in peer set
1-month return-8.6%-2.4%6th lowest of 20
6-month return-32.5%-7.3%3rd lowest of 20
Distance from 52-week high-52.6%-33.7%3rd lowest of 20
Revenue growth (TTM)+2.8%+3.5%9th lowest of 19
Operating margin18.5%8.8%4th highest of 19
Forward P/E7.1×16.1×cheapest of 6
Growth the price implies (Req g, 7 yrs)-11.8%4.0%least demanding of 12
Growth delivered (Del g)+1.9%+0.5%6th highest of 12
Hurdle (Req g minus delivered)-13.7 pp-1.4 pp2nd least demanding of 12
ROIC minus cost of capital-2.0 pp+0.4 pp4th lowest of 17
EV / EBITDA3.4×8.3×cheapest of 5
Net debt / EBITDA-0.2×-1.2×2nd most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Luye Pharma 2186.HKHong Kong$736M-32%+3%18%7.1×-11.8%+1.9%
Hunan Jiudian Pharmaceutical 300705.SZChina$738M-20%-5%13%16.7×-2.0%+26.1%
Jiangsu Jibeier Pharmaceutical 688566.SSChina$727M-9%+8%26%11.2×5.9%+11.3%
Shanghai Jiaoda Onlly 600530.SSChina$726M-25%-2%-2%n/a42.7%-0.9%
Zhuzhou Qianjin Pharmaceutical 600479.SSChina$746M-3%+4%11%n/a-2.1%0.0%
Hunan Warrant Pharmaceutical 688799.SSChina$725M-34%-3%9%47.6×n/an/a
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%n/an/an/a
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%n/a9.4%-1.4%
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%13.7×-4.8%+6.4%
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%n/a13.5%-0.2%
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%n/an/an/a
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%16.1×n/an/a
Katakura Industries 3001.TJapan$765M+40%-2%15%n/a0.3%+0.5%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%n/an/an/a
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%n/a-3.8%-0.8%
HPGC Renmintongtai Pharmaceutical 600829.SSChina$701M-6%+4%2%n/a4.0%+5.3%
Nuvectis Pharma NVCTUnited States$698M+91%n/an/an/an/an/a
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%n/a33.9%+10.1%
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%n/an/an/a

Questions

Which companies are Luye Pharma's closest peers?
The cockpit's peer set: Hunan Jiudian Pharmaceutical (300705.SZ), Jiangsu Jibeier Pharmaceutical (688566.SS), Shanghai Jiaoda Onlly (600530.SS), Zhuzhou Qianjin Pharmaceutical (600479.SS), Hunan Warrant Pharmaceutical (688799.SS), Sagimet Biosciences (SGMT), CARsgen Therapeutics (2171.HK), Chongqing Pharscin Pharmaceutical (002907.SZ).
Is Luye Pharma expensive compared with its peers?
On forward p/e it trades at 7.1× against a peer median of 16.1×, cheapest of 6 in its peer set. For today's price to make sense, revenue must grow about -12% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -14 pp: the price already allows for a slowdown.
How has Luye Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned -32.5% against -7.3% for the median peer; over one year -50.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.